Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial

Blockade of ActRIIB Signaling Triggers Muscle Fatigability and Metabolic Myopathy

(2014) Karima Relizani et al.   MOLECULAR THERAPY

Inhibition of myostatin reverses muscle fibrosis through apoptosis

(2012) Zhao Bo Li et al.   JOURNAL OF CELL SCIENCE

A single ascending-dose study of muscle regulator ace-031 in healthy volunteers

(2012) Kenneth M. Attie et al.   MUSCLE & NERVE

Targeting the Activin Type IIB Receptor to Improve Muscle Mass and Function in the mdx Mouse Model of Duchenne Muscular Dystrophy

(2011) Emidio E. Pistilli et al.   AMERICAN JOURNAL OF PATHOLOGY

Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse

(2011) C. George Carlson et al.   MUSCLE & NERVE

Duchenne Muscular Dystrophy: A 30-Year Population-Based Incidence Study

(2010) Joseph Dooley et al.   CLINICAL PEDIATRICS

Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type

(2010) Samuel M. Cadena et al.   JOURNAL OF APPLIED PHYSIOLOGY

Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of duchenne muscular dystrophy

(2010) Kevin J. Morine et al.   MUSCLE & NERVE

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

(2009) Katharine Bushby et al.   LANCET NEUROLOGY

A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy

(2008) Kathryn R. Wagner et al.   ANNALS OF NEUROLOGY